Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

· manilatimes.net

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027

Phase 2 CIPheR trial of MZE782 in PKU initiat...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI